D
Dean E. Schraufnagel
Researcher at University of Illinois at Chicago
Publications - 174
Citations - 9217
Dean E. Schraufnagel is an academic researcher from University of Illinois at Chicago. The author has contributed to research in topics: Lung & Health care. The author has an hindex of 41, co-authored 169 publications receiving 7493 citations. Previous affiliations of Dean E. Schraufnagel include Montreal Children's Hospital & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Cyclophosphamide versus placebo in scleroderma lung disease.
Donald P. Tashkin,Robert Elashoff,Philip J. Clements,Jonathan G. Goldin,Michael D. Roth,Daniel E. Furst,Edgar Arriola,Richard M. Silver,Charlie Strange,Marcy B. Bolster,James R. Seibold,David J. Riley,Vivien Hsu,John Varga,Dean E. Schraufnagel,Arthur C. Theodore,Robert W. Simms,Robert A. Wise,Fredrick M. Wigley,Barbara White,Virginia D. Steen,Charles A. Read,Maureen D. Mayes,Ed Parsley,Kamal K. Mubarak,M. Kari Connolly,Jeffrey A. Golden,Mitchell A. Olman,B. J. Fessler,Naomi F. Rothfield,Mark L. Metersky +30 more
TL;DR: One year of oral cyclophosphamide in patients with symptomatic scleroderma-related interstitial lung disease had a significant but modest beneficial effect on lung function, dyspnea, thickening of the skin, and the health-related quality of life.
Journal ArticleDOI
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
Donald P. Tashkin,Michael D. Roth,Philip J. Clements,Daniel E. Furst,Dinesh Khanna,Eric C. Kleerup,Jonathan G. Goldin,Edgar Arriola,Elizabeth R. Volkmann,Suzanne Kafaja,Richard M. Silver,Virginia D. Steen,Charlie Strange,Robert A. Wise,Fredrick M. Wigley,Maureen D. Mayes,David J. Riley,Sabiha Hussain,Shervin Assassi,Vivien Hsu,Bela Patel,Kristine Phillips,Fernando J. Martinez,Jeffrey A. Golden,M. Kari Connolly,John Varga,Jane Dematte,Monique Hinchcliff,Aryeh Fischer,Jeffrey J. Swigris,Richard T. Meehan,Arthur C. Theodore,Robert W. Simms,Suncica Volkov,Dean E. Schraufnagel,Mary Beth Scholand,Tracy M. Frech,Jerry A. Molitor,Kristin B. Highland,Charles A. Read,Marvin J. Fritzler,Grace Kim,Chi-Hong Tseng,Robert Elashoff +43 more
TL;DR: In this article, the authors used a modified intention-to-treat analysis using an inferential joint model combining a mixed-effects model for longitudinal outcomes and a survival model to handle non-ignorable missing data.
Journal ArticleDOI
The global burden of respiratory disease.
TL;DR: Implementation of the strategies described in the Forum of International Respiratory Societies respiratory diseases report would have a profound effect on respiratory health, reduce economic costs, and enhance health equality in the world.
Journal ArticleDOI
Air Pollution and Noncommunicable Diseases: A Review by the Forum of International Respiratory Societies' Environmental Committee, Part 2: Air Pollution and Organ Systems.
Dean E. Schraufnagel,John R. Balmes,Clayton T. Cowl,Sara De Matteis,Soon Hee Jung,Kevin Mortimer,Rogelio Pérez-Padilla,Mary B. Rice,Horacio Riojas-Rodríguez,Akshay Sood,George D. Thurston,Teresa To,Anessa Vanker,Donald J. Wuebbles +13 more
TL;DR: Air pollution affects the immune system and is associated with allergic rhinitis, allergic sensitization, and autoimmunity, and it is also associated with osteoporosis and bone fractures, conjunctivitis, dry eye disease, blepharitis, inflammatory bowel disease, increased intravascular coagulation, and decreased glomerular filtration rate.
Journal ArticleDOI
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
Donald P. Tashkin,Robert Elashoff,Philip J. Clements,Michael D. Roth,Daniel E. Furst,Richard M. Silver,Jonathan G. Goldin,Edgar Arriola,Charlie Strange,Marcy B. Bolster,James R. Seibold,David J. Riley,Vivien Hsu,John Varga,Dean E. Schraufnagel,Arthur C. Theodore,Robert W. Simms,Robert A. Wise,Fred M. Wigley,Barbara White,Virginia D. Steen,Charles A. Read,Maureen D. Mayes,Ed Parsley,Kamal K. Mubarak,M. Kari Connolly,Jeffrey A. Golden,Mitchell A. Olman,Barri J. Fessler,Naomi F. Rothfield,Mark L. Metersky,Dinesh Khanna,Ning Li,Gang Li +33 more
TL;DR: One year of CYC improved lung function, skin scores, dyspnea, and health status/disability, effects which either persisted or increased further for several months after stopping therapy, but all of these effects waned and were no longer apparent at 24 months.